See article, [p. 526][1] .
![][2] Approximately 7% of estrogen receptor–positive (ER+) breast cancers harbor mutations in AKT1 (most often E17K) that cause PI3K-pathway activation. However, due to the rarity of this genomically defined breast cancer subgroup, the potential

中文翻译：

---

在这个问题上

参见文章[p。526] [1]。
！[] [2]大约7％的雌激素受体阳性（ER +）乳腺癌中存在导致PI3K途径活化的AKT1突变（最常见的是E17K）。然而，由于该基因组定义的乳腺癌亚组的罕见性，潜在的